Viridian Therapeutics, Inc. (LON:0K1R)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.35B +59.2% |
| Revenue (ttm) | 53.71M +23,382.8% |
| Net Income | -229.67M |
| EPS | -2.55 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,374 |
| Open | 16.50 |
| Previous Close | 16.04 |
| Day's Range | 16.25 - 16.68 |
| 52-Week Range | 13.25 - 34.31 |
| Beta | 0.90 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About Viridian Therapeutics
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o... [Read more]
Financial Performance
In 2025, Viridian Therapeutics's revenue was $70.85 million, an increase of 23359.93% compared to the previous year's $302,000. Losses were -$281.93 million, 35.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Viridian Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Commercial approval is expected by June 30, with full operational readiness and a trained sales force targeting 2,000 core prescribers. Differentiated clinical data and subcutaneous options position the portfolio for broad adoption in both active and chronic thyroid eye disease.
Viridian Metals Commences 2026 Diamond Drill Program at the Kraken
OTTAWA, June 09, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) announces that diamond drilling has commenced at its Kraken Copper-Nickel-Cobalt Project in Lab...
Viridian Metals Highlights Copper-Rich Zones up to 4.15% Cu at Kraken Ahead of 2026 Drill Program
OTTAWA, Ontario, June 05, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is advancing plans to target high-grade copper-rich zones identified within the Kraken...
Viridian Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Advancing TED therapies with a PDUFA date in June 2026, the company is ready for commercial launch and expects strong market expansion with IV and subQ options. Financially robust, it targets broad access and sees significant opportunity in both active and chronic TED.
Viridian Therapeutics Slides: Corporate presentation
Viridian Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Metals Expands Drill Program to 50 Holes at Kraken Copper-Nickel Project
OTTAWA, Ontario, May 19, 2026 (GLOBE NEWSWIRE) -- Viridian Metals (CSE: VRDN) (“Viridian” or the “Company”) will commence a minimum 50-hole drill program in early June at its Kraken Copper-Nickel Proj...
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
Evercore ISI lowered the firm’s price target on Viridian Therapeutics (VRDN) to $26 from $27 and keeps an Outperform rating on the shares.
Viridian Metals Announces Flow-Through Private Placement, Warrant Extension and Date of Annual General and Special Meeting
OTTAWA, May 14, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (“Viridian” or the “Company”) is pleased to announce that it has entered into a binding subscription agreement with Pavilion F...
Viridian Therapeutics price target lowered to $39 from $48 at Stifel
Stifel lowered the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $48 and keeps a Buy rating on the shares. The firm has modeled a slower franchise ramp…
Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00
The deal size was increased to $125M in common stock from $100M in common stock. Jefferies, Leerink and Goldman Sachs acted as joint book running managers for the offering. Published…
Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $34 from $30 and keeps an Outperform rating on the shares after its Q1 results. On ele’, RBC…
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoim...
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoim...
Viridian Therapeutics Transcript: Study result
REVEAL-2, the largest pivotal trial in chronic TED, showed Ellay met all primary and key secondary endpoints with strong efficacy and a favorable safety profile. Both Q4 and Q8 dosing regimens offer IV-like results in a convenient auto-injector, supporting plans for regulatory submission and broad market expansion.
Viridian Therapeutics Press release: Study result
Viridian Therapeutics issued a press release on May 5, 2026, disclosing material business information to investors.
Viridian Therapeutics Slides: Study result
Viridian Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Viridian announces REVEAL-2 phase 3 study met primary endpoint
Viridian Therapeutics (VRDN) announced positive topline data from the REVEAL-2 phase 3 clinical trial of elegrobart in patients with chronic thyroid eye disease, TED. Elegrobart is a subcutaneously de...
Viridian Therapeutics reports Q1 EPS (90c), consensus ($1.09)
Reports Q1 revenue $141k, consensus $27.75k. “Our team continues its strong execution across our portfolio as we are launch ready ahead of veligrotug’s PDUFA target date. We delivered positive topline...
Viridian eye disease drug benefits chronic patients in late-stage trial
Viridian Therapeutics said on Tuesday its experimental thyroid eye disease drug met the main goal of a late-stage trial in chronic patients.
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for aut...
Viridian Therapeutics Quarterly report: Q1 2026
Viridian Therapeutics has published its Q1 2026 quarterly earnings report on May 5, 2026.
Viridian Therapeutics Earnings release: Q1 2026
Viridian Therapeutics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Viridian Therapeutics Slides: Corporate presentation
Viridian Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.